The DGAT inhibitor, PF-06424439, has been confirmed in vitro studies of colorectal and breast cancer to have a positive role in enhancing the anti-tumor effects of 5-fluorouracil, cisplatin, and even radiotherapy [297–299]. Here, DGAT1 is linked to neoplasm.